^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Tongue Carcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Concurrent EGFR wild-type tongue squamous cell carcinoma and EGFR-mutant lung adenocarcinoma and response to osimertinib.
Published date:
05/25/2023
Excerpt:
We found a...patient who...had tongue squamous cell carcinoma with EGFR wild-type….PET-CT scans demonstrated a partial response (PR) of the...tongue cancer after two months of treatment of osimertinib...the tongue tumor reached the first progression- free survival (PFS) at 21 months....The result indicates a clear response of tongue cancer to osimertinib...
DOI:
10.1200/JCO.2023.41.16_suppl.e18074
